

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/13, C07K 16/36, 16/42, A61K 39/395, 38/37, C12Q 1/68 // (A61K 39/395, 38/37)		A2	(11) International Publication Number: WO 99/58680 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/NL99/00285		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 7 May 1999 (07.05.99)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 98201543.0 8 May 1998 (08.05.98) EP			
(71) Applicant (for all designated States except US): STICHTING SANQUIN BLOEDVOORZIENING [NL/NL]; Plesmanlaan 125, NL-1066 CX Amsterdam (NL).			
(72) Inventors; and (75) Inventors/Applicants (for US only): VOORBERG, Johannes, Jacobus [NL/NL]; Klokkeemeet 22, NL-1566 RH Assendelft (NL). VAN DEN BRINK, Edward, Norbert [NL/NL]; Valkenisseweg 105, NL-1069 BX Amsterdam (NL). TURENHOUT, Ellen, Anne, Maria [NL/NL]; Lavendel 19, NL-2211 MV Noordwijkerhout (NL).			
(74) Agent: OTTEVANGERS, S., U.; Vereenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).			

(54) Title: METHOD FOR DIAGNOSIS AND TREATMENT OF HAEMOPHILIA A PATIENTS WITH AN INHIBITOR

(57) Abstract

A polynucleotide, comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity, or complementary to a nucleotide sequence coding for a human antibody with factor VIII specificity, or capable of selectively hybridizing under stringent conditions to such nucleotide sequence. Such polynucleotide may be used as a probe or primer for detection of factor VIII inhibitors, or be used for producing a recombinant polypeptide. A polypeptide, comprising a contiguous amino acid sequence corresponding to or mimicking a fragment or derivative of a human antibody with factor VIII specificity capable of specific binding to factor VIII. An antibody, comprising a recombinant human antibody with factor VIII specificity or an anti-idiotypic antibody directed against a human antibody with factor VIII specificity. Pharmaceutical compositions which contain such polypeptide or antibody.